Author: Marc Lichtenfeld, Wealthy Retirement

The company’s financials look pristine.

I don’t foresee it having a problem affording its dividend…

It’s one of the few biotech companies that are very profitable and cash flow positive and can afford to pay dividends.

If you think you don’t own it so you don’t really need to be concerned, well, lots of mutual funds own it.

Trading at one of the lowest valuations in the company’s history, if the proposed merger goes through investors who buy shares at current prices are going to make out very well in a hurry.